<table>
<thead>
<tr>
<th>Title</th>
<th>ITPKA expression is a novel prognostic factor in hepatocellular carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>LI, JB; Zhu, YH; Huang, PZ; Zhang, BZ; Sun, J; Guan, X</td>
</tr>
<tr>
<td>Citation</td>
<td>Diagnostic Pathology, 2015, v. 10, p. 136:1-8</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2015</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/244867">http://hdl.handle.net/10722/244867</a></td>
</tr>
<tr>
<td>Rights</td>
<td>Diagnostic Pathology. Copyright © BioMed Central Ltd.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
ITPKA expression is a novel prognostic factor in hepatocellular carcinoma

Jianbiao Li1†, Ying-Hui Zhu1†, Pinzhu Huang3, Baozhu Zhang1, Jian Sun1* and Xin-Yuan Guan1,2*

Abstract

Background: Inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) has recently been found to be implicated in the tumor progression of various cancers. However, the expression and the prognostic value of ITPKA in hepatocellular carcinoma (HCC) remains unexplored. The aim of this study is to investigate the clinical significance of ITPKA expression in HCC.

Methods: We determined the expression level of ITPKA in 135 cases of HCC tissues and the matched adjacent nontumorous tissues by quantitative real-time RT-PCR. The correlation between ITPKA expression and prognosis of HCC patients was further evaluated by univariate and multivariate analysis. Multivariate analysis of the prognostic factors was performed with Cox proportional hazards model.

Results: Up-regulation of ITPKA occurred in 48.9 % of primary HCCs compared with their nontumor counterparts (P < 0.001). In addition, high expression of ITPKA was significantly associated with vascular invasion (P = 0.001) and TNM stage (P = 0.005). Kaplan–Meier analysis showed that the 5-year overall survival (OS) and relapse-free survival (RFS) rate in the group with high expression of ITPKA is poorer than that in low expression group (32.2 and 26.8 % versus 59.2 and 57.7 %). Univariate and multivariate analyses revealed that ITPKA was an independent prognostic factor for OS and RFS. Moreover, Stratified analysis revealed that its prognostic significance still existed within the subgroup of patients with early clinical stage (TNM stage I) or normal serum AFP level (≤ 25 μg/L).

Conclusion: Our data indicated that ITPKA expression was significantly up-regulated in HCC and could serve as a potential novel prognostic biomarker for HCC patients after surgery.

Background

Hepatocellular carcinoma (HCC) is a highly lethal cancer, which has been ranked as the fifth most common malignancy and the third leading cause of cancer-related mortality worldwide [1–4]. Despite of the tremendous progress in diagnosis and multimodality treatment in the past decades, the prognosis of HCC patients remains grim, mainly because of its high recurrent and metastatic rate [5]. To date, numerous studies have identified a mass of dysregulated molecular events involved in liver carcinogenesis, which cover a wide range of genes with various functions. However, the biomarkers for HCC remain unsatisfactory in terms of high-risk population screening, clinical diagnosis and prognosis, and evaluation of treatment efficiency. Therefore, it is imperative to identify and characterize novel biomarkers for this disease.

With the advent of high-throughput sequencing technologies in recent years, transcriptome sequencing (RNA-Seq) has been a powerful tool for gene expression profiling in the study of cancer. Recently, our group exploited a RNA-Seq to delineate differential gene expression in ten pairs of HCC and nontumor clinical samples. Overexpression of inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) was observed in all ten HCC tumor tissues compared with their matched nontumoral counterparts. ITPKA gene, which is located in 15q15, encodes a predicted 461 amino acid polypeptide. Under physiological conditions, ITPKA is only identified in neurons and testis [6]. It is one of the three inositol trisphosphate 3-kinases (ITPKs) isoforms (A, B and C) that catalyse the phosphorylation of the second messenger inositol
1,4,5-trisphosphate (Ins(1, 4, 5)P₃) to inositol 1, 3, 4, 5-
tetrakisphosphate (Ins(1, 3, 4, 5)P₄), and thus regulate
Ins(1, 4, 5)P₃-induced calcium (Ca²⁺) signals [7, 8]. In-
dependent of this catalytic activity, ITPKA also binds and
bundles filamentous actin (F-actin) to regulate the spine
morphology [9]. Beside these physiological roles, ITPKA
plays an important role in the carcinogenesis and meta-
tasis. Down-regulated ITPKA expression was identified
in oral squamous cell carcinoma (OSCC) tissues and
OSCC cell lines [10]. Whereas in contrast, recent studies
on lung cancer showed that high expression of ITPKA
was detected in primary tumors and the matched lymph
node metastases [11]. Furthermore, the analysis of RNA-
seq data for kidney renal clear cell carcinoma patients
showed that up-regulated ITPKA expression was associ-
ated with advanced stage and lower survival rates [12].
Taken together, we hypothesize that ITPKA may be a
useful metastasis and prognostic marker for HCC.

In the present study, we investigated the expression
levels of ITPKA in HCC and their paired adjacent non-
tumorous tissues, and further evaluated the correlation
of ITPKA expression with clinical parameters and its
prognostic value in HCC.

Methods

Patients and tissue samples

One hundred thirty five paired primary HCC tumor
and nontumorous tissue samples were collected im-
mediately after surgery resection at Sun Yat-sen
University Cancer Center between December 2003 and
September 2009. The enrollment criteria were as follows:
(a) definitive HCC diagnosis by pathology based on WHO
criteria; (b) no preoperative trans-hepatic arterial chemo-
embolization or chemotherapy or radiotherapy before
surgery; (c) surgical resection, defined as complete re-
section of all tumor nodules with the cut surface being
free of cancer by histologic examination; (d) complete
clinicopathologic and follow-up data. Ethical approval for
this study was granted by the Medical Ethics Committee
of Sun Yat-sen University Cancer Center. All patients
signed informed consent. In this study, nontumoral liver
tissues were defined as 2.0 cm from the tumor margin,
which had been described previously [13]. Hepatitis B
history was defined as history with positive serum
hepatitis B surface antigen (HBsAg). Tumor encapsu-
lation was defined as the presence of a clear fibrous
sheath around the tumor at gross inspection. Tumor
differentiation was based on the Edmondson and
Steiner classification. HCC metastasis was defined as
the presence of vascular invasion in the portal vein or
the presence of satellite nodules surrounding a larger
main tumor [14]. Tumor staging was determined ac-
cording to the 7th edition tumor-node-metastasis
(TNM) classification of the American Joint Committee
on Cancer.

Cell lines and culture conditions

HCC cell lines BEL7402, Hep3B, PLC8024, QGY7701,
QGY7703, SMMC7721 and immortalized liver cell line
LO2 were obtained from the Institute of Virology,
Chinese Academy of Medical Sciences (Beijing, China).
Huh7 was purchased from American type culture col-
lection (ATCC, Manassas, Virginia, USA). Cells were
maintained in high-glucose DMEM (Gibco BRL, Grand
Island, NY) supplemented with 10 % fetal bovine serum
(FBS) (Gibco BRL, Grand Island, NY). The cells were
incubated at 37 °C in a humidified incubator containing
5 % CO₂.

Quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR)

All fresh tumorous and nontumorous tissue samples
were immediately stored at dry ice after resection and
then frozen at –80 °C. Total RNA was extracted from
clinical samples or cell lines using TRizol reagent (Invi-
trogen), and was reverse-transcribed using an Advantage
RT-for-PCR Kit (Clontech Laboratories) according to
the manufacturer’s instructions. qRT-PCR was performed
to detect levels of the corresponding glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and ITPKA using a
SYBR Green PCR Kit (Applied Biosystems) and Light-
Cycler480 384-well PCR system (Roche Diagnostics).
The GAPDH was used as an internal control for
ITPKA. Primers for ITPKA are 5'-CCCTTCCACCTC
GTCGGTCT-3' (forward) and 5'-GCCGTTAAACCT
CACCAGTGTCG-3' (reverse). Primers for GAPDH are
5'-ACTTTCAACAGCGACCCACCTC-3' (forward) and
5'-TACCAGGAATGAGCTTGACAA-3' (reverse).
The value of relative expression for each sample was averaged
and compared using the Ct method. ΔΔCt(sample) =
ΔCt(sample) - ΔCt(calibrator), ΔCt(sample) = Ct(sample) of
ITPKA - Ct(sample) of GAPDH; ΔCt(calibrator) = Ct(calibrator)
of ITPKA - Ct(calibrator) of GAPDH; calibrator was
defined as the pooled samples from 135 adjacent non-
tumorous tissues.

Western blot analysis

ITPKA protein expression in cell lines was detected by
Western blotting. Briefly, cells were washed twice with
ice-cold PBS. Total protein was extracted with lysis
buffer for 45 min on ice. Equal amounts of protein
were separated by 12 % SDS-PAGE and electrophoret-
cally transferred to polyvinylidene difluoride mem-
branes (Millipore) using a mini trans-blot apparatus
(Bio-Rad Laboratories). Membranes were blocked with
PBS-0.05 % Tween 20 containing 5 % nonfat dry milk
for one hour at room temperature and incubated with
polyclonal rabbit anti-ITPKA (1:1,000; Proteintech) or monoclonal mouse anti-GAPDH antibody (1:5,000; Vazyme Biotech) at 4 °C overnight. Membranes were then washed three times with PBS-0.05 % Tween 20 and incubated with horseradish peroxidase–conjugated goat anti-rabbit or anti-mouse IgG (Santa Cruz Biotechnology) at a 1:5,000 dilution for one hour at room temperature. Blots were developed using an enhanced chemiluminescence kit (Pierce). Each experiment was repeated at least three times.

Fig. 1 ITPKA was up-regulated in HCCs. **, \( P < 0.001 \), paired \( t \)-test. Ap- Up-regulation of ITPKA was detected in 4 of 7 HCC cell lines by qRT-PCR (upper) and western blot analysis (lower). Immortalized liver cell line (LO2) was used as control.
Statistical analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 16.0 (SPSS Inc, Chicago, IL). Paired two-tailed student’s t test was used to compare the expression of ITPKA in primary HCC tumors and their corresponding adjacent nontumorous tissues. The correlation between ITPKA expression and clinicopathological parameters was assessed by chi-square test or Fisher’s exact test. Disease-specific survival was calculated from the time of surgery to either the time of death from HCC or last follow up (31 December 2014). The prognostic value was calculated by the Kaplan-Meier analysis with log-rank test. Univariate and multivariate survival analysis was performed using the Cox proportional hazard model with a forward stepwise procedure (the entry and removal probabilities were 0.05 and 0.10, respectively). A significant difference was considered statistically when P value was <0.05.

Results
ITPKA expression was up-regulated in HCC
Our prior RNA-seq profiling data showed that ITPKA was overexpressed in all ten tested HCC tumor tissues. High expression of ITPKA (defined as >2-fold change) was detected in 66 of 135 (48.9 %) of HCC tissues by qRT-PCR, compared with their normal counterparts. The average level of ITPKA expression in tumor tissues was significantly higher than that in non-tumor tissues (1.11 versus 3.01, P<0.001, paired Student’s t test; Fig. 1a). The median fold change of ITPKA (1.84) in HCC tumor tissues was used as a cutoff value to divide all 135 patients into two groups: the high expression group (n = 66) and the low expression group (n = 69). The expression levels of ITPKA in seven HCC cell lines and one immortalized liver cell line (LO2) were tested by qRT-PCR and western blot analysis. Compared with LO2, up-regulation of ITPKA was detected in QGY7703, Hep3B, Huh7 and PLC8024 cells (Fig. 1b).

Clinicopathologic features of ITPKA in HCC patients
The correlation between ITPKA mRNA expression in primary HCC and clinicopathological features was summarized in Table 1. High expression of ITPKA was significantly associated with vascular invasion (P = 0.001) and TNM stage (P = 0.005). No correlation was observed between ITPKA expression and other clinicopathological characteristics.

Association between ITPKA expression and patient survival
Univariate analysis showed that HBsAg, serum AFP level, tumor size, tumor number, vascular invasion, TNM stage, and ITPKA expression were prognostic factors for OS and RFS (Table 2). The 5-year OS and RFS rate in the high ITPKA expression group were significantly lower than those in the low ITPKA expression group (32.2 and 26.8 % versus 59.2 and 57.7 %; Fig. 2a). Considering that the TNM stage was correlated with several clinical indexes (such as tumor size, tumor number, and vascular invasion), we did not introduce it into the multivariate Cox proportional hazard model to avoid potential bias.

<p>| Table 1 Association of ITPKA expression with clinicopathological features in HCCs |
|-----------------|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Cases</th>
<th>ITPKA expression</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>low level (%)</td>
<td>high level (%)</td>
<td>P value</td>
</tr>
<tr>
<td>Age (years old)</td>
<td>63</td>
<td>32 (50.8 %)</td>
<td>31 (49.2 %)</td>
</tr>
<tr>
<td>≤50</td>
<td>72</td>
<td>37 (51.4 %)</td>
<td>35 (48.6 %)</td>
</tr>
<tr>
<td>&gt;50</td>
<td>128</td>
<td>65 (50.8 %)</td>
<td>63 (49.2 %)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7</td>
<td>4 (57.1 %)</td>
<td>3 (42.9 %)</td>
</tr>
<tr>
<td>Female</td>
<td>10</td>
<td>1 (100 %)</td>
<td>9 (90.0 %)</td>
</tr>
<tr>
<td>HBsAg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>15</td>
<td>10 (66.7 %)</td>
<td>5 (33.3 %)</td>
</tr>
<tr>
<td>Positve</td>
<td>120</td>
<td>59 (49.2 %)</td>
<td>61 (50.8 %)</td>
</tr>
<tr>
<td>AFP (μg/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤25</td>
<td>48</td>
<td>28 (58.3 %)</td>
<td>20 (41.7 %)</td>
</tr>
<tr>
<td>&gt;25</td>
<td>87</td>
<td>41 (47.1 %)</td>
<td>46 (52.9 %)</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>23</td>
<td>13 (56.5 %)</td>
<td>10 (43.5 %)</td>
</tr>
<tr>
<td>Yes</td>
<td>112</td>
<td>56 (50.0 %)</td>
<td>56 (50.0 %)</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5</td>
<td>56</td>
<td>33 (58.9 %)</td>
<td>23 (41.1 %)</td>
</tr>
<tr>
<td>&gt;5</td>
<td>79</td>
<td>36 (45.6 %)</td>
<td>43 (54.4 %)</td>
</tr>
<tr>
<td>Tumor number</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solitary</td>
<td>104</td>
<td>57 (54.8 %)</td>
<td>47 (45.2 %)</td>
</tr>
<tr>
<td>Multiple</td>
<td>31</td>
<td>12 (38.7 %)</td>
<td>19 (61.3 %)</td>
</tr>
<tr>
<td>Tumor encapsulation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>43</td>
<td>24 (55.8 %)</td>
<td>19 (44.2 %)</td>
</tr>
<tr>
<td>None</td>
<td>92</td>
<td>45 (48.9 %)</td>
<td>47 (51.1 %)</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>114</td>
<td>65 (57.0 %)</td>
<td>49 (43.0 %)</td>
</tr>
<tr>
<td>Present</td>
<td>21</td>
<td>4 (19.0 %)</td>
<td>17 (81.0 %)</td>
</tr>
<tr>
<td>Edmondson-Steiner</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>79</td>
<td>45 (57.0 %)</td>
<td>34 (43.0 %)</td>
</tr>
<tr>
<td>III-IV</td>
<td>56</td>
<td>24 (42.9 %)</td>
<td>32 (57.1 %)</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>93</td>
<td>55 (59.1 %)</td>
<td>38 (40.9 %)</td>
</tr>
<tr>
<td>II-III</td>
<td>42</td>
<td>14 (33.3 %)</td>
<td>28 (66.7 %)</td>
</tr>
</tbody>
</table>

Statistical significance (P < 0.05) is shown in bold.
multivariate analysis demonstrated that ITPKA expression, HBsAg and vascular invasion were independent prognostic predictors for RFS (Table 3). Further, in a stratified survival analysis according to the TNM stage or serum AFP level, we found that the prognostic significance of ITPKA was retained in TNM stage I ($P = 0.001$), normal AFP level ($\leq 25 \mu g/L; P = 0.047$) and high AFP level ($>25 \mu g/L; P = 0.001$) subgroups (Fig. 2b and c).

**Discussion and conclusions**

The intracellular second messenger Ins(1,4,5)P$_3$ controls many different cellular functions by regulating internal Ca$^{2+}$ signals [7]. The lifetime of Ins(1,4,5)P$_3$ is tightly regulated by two mechanisms: phosphorylation via ITPKs to Ins(1,3,4,5)P$_4$ or dephosphorylation via ins(1,4,5)P$_3$ 5-phosphatase (INPP5A) to inositol 1,4-bisphosphate (Ins(1,4)P$_2$) [15, 16]. ITPKA is the most highly characterized ITPKs isofrom, and found up-regulated in lung cancer tumor tissues [11]. In the present study, our data demonstrated that 48.9 % of HCC patients showed elevated ITPKA expression in their tumorous specimens compared with their normal counterparts. However, down-regulation of ITPKA was found in oral squamous cell carcinoma, suggesting that ITPKA may serve as a tumor-suppressor [10]. Based on these studies, the function of ITPKA seems to depend on its cellular context.

We next investigated the clinicopathologic correlation of ITPKA expression in HCC patients. The results showed that overexpression of ITPKA correlated with vascular invasion ($P = 0.001$) and TNM stage ($P = 0.005$), which strongly suggested that ITPKA was involved in the metastasis and progression of HCC. This is in an agreement with two recent studies, which showed that ectopic expression of ITPKA enhanced the metastatic potential of tumor cells [11, 17]. Ca$^{2+}$ is a ubiquitous second messenger that mediates numerous cellular processes, including cell proliferation, survival, apoptosis, migration and gene expression. Increases of intracellular Ca$^{2+}$ concentration have long been known to be involved in cell migration and invasion. Ins(1,4,5)P$_3$ can bind to the ER membrane Ca$^{2+}$-permeable Ins(1,4,5)P$_3$ receptor (IP$_3$R) channels, which results in the opening of the membrane channel, and further release the stored Ca$^{2+}$ into the cytosol [18, 19]. ITPKA metabolizes Ins(1,4,5)P$_3$ to Ins(1,3,4,5)P$_4$, which in turn terminates the signal to release Ca$^{2+}$ from the endoplasmic reticulum. On the other hand, in some cases the Ins(1,3,4,5)P$_4$ produced by ITPKA, can protect Ins(1,4,5)P$_3$ by competitively inhibiting the activity of INPP5A and thus prolongs the effect of Ins(1,4,5)P$_3$ on Ca$^{2+}$ signals [20, 21]. Moreover, a recent report demonstrated that in EGF-stimulated tumor cells Ins(1,3,4,5)P$_4$ prolonged Ca$^{2+}$ signaling by activation of SOCE [17]. Hence, we speculated that ITPKA might enhance the metastatic potential of HCC cells by increasing intracellular Ca$^{2+}$ concentration. However, further studies are required to elucidate the function and mechanisms of ITPKA that involved in the Ca$^{2+}$ signaling in HCC. During metastatic dissemination, cancer cells must acquire the ability to migrate, which is correlated with cytoskeletal remodeling. Independent of its InsP$_3$ kinase activity, ITPKA can modify spine shape and internal microstructure by directly binding and bundling actin filaments and/or by recruiting Rac1 and associated signaling machinery [9, 22]. It has also been shown that ITPKA induces the formation of filopodia- and lamellipodia-like protrusions, and consequently enhances the migratory and invasive abilities of tumor cells.

### Table 2: Univariate Cox regression analyses for OS and RFS in HCCs

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>OS (HR 95 % CI)</th>
<th>P value</th>
<th>RFS (HR 95 % CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.678 (0.420–1.096)</td>
<td>0.113</td>
<td>0.653 (0.409–1.041)</td>
<td>0.073</td>
</tr>
<tr>
<td>Gender</td>
<td>2.297 (0.562–9.390)</td>
<td>0.247</td>
<td>2.526 (0.619–10.316)</td>
<td>0.197</td>
</tr>
<tr>
<td>HBsAg</td>
<td>3.379 (1.061–10.763)</td>
<td><strong>0.039</strong></td>
<td>3.581 (1.126–11.394)</td>
<td><strong>0.031</strong></td>
</tr>
<tr>
<td>AFP</td>
<td>2.187 (1.246–3.839)</td>
<td><strong>0.006</strong></td>
<td>2.000 (1.171–3.418)</td>
<td><strong>0.011</strong></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>1.025 (0.549–1.916)</td>
<td>0.937</td>
<td>1.127 (0.605–2.097)</td>
<td>0.707</td>
</tr>
<tr>
<td>Tumor size</td>
<td>2.161 (1.279–3.653)</td>
<td><strong>0.004</strong></td>
<td>1.870 (1.135–3.081)</td>
<td><strong>0.014</strong></td>
</tr>
<tr>
<td>Tumor number</td>
<td>2.475 (1.488–4.118)</td>
<td>&lt;<strong>0.001</strong></td>
<td>2.576 (1.574–4.216)</td>
<td>&lt;<strong>0.001</strong></td>
</tr>
<tr>
<td>Tumor encapsulation</td>
<td>0.674 (0.392–1.161)</td>
<td>0.155</td>
<td>0.722 (0.429–1.215)</td>
<td>0.221</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td>6.074 (3.449–10.698)</td>
<td>&lt;<strong>0.001</strong></td>
<td>5.722 (3.236–10.119)</td>
<td>&lt;<strong>0.001</strong></td>
</tr>
<tr>
<td>Edmondson-Steiner</td>
<td>1.348 (0.832–2.186)</td>
<td>0.225</td>
<td>1.296 (0.810–2.074)</td>
<td>0.279</td>
</tr>
<tr>
<td>TNM stage</td>
<td>4.919 (3.014–8.082)</td>
<td>&lt;<strong>0.001</strong></td>
<td>4.282 (2.654–6.907)</td>
<td>&lt;<strong>0.001</strong></td>
</tr>
<tr>
<td>ITPKA expression</td>
<td>2.579 (1.567–4.245)</td>
<td>&lt;<strong>0.001</strong></td>
<td>2.669 (1.638–4.349)</td>
<td>&lt;<strong>0.001</strong></td>
</tr>
</tbody>
</table>

HR hazard ratio; CI confidence interval; statistical significance ($P < 0.05$) is shown in bold.
Fig. 2 Kaplan-Meier analysis of OS and RFS for ITPKA expression. a Kaplan-Meier analysis of OS and RFS for ITPKA expression in 135 cases of HCC patients. b Stratified survival analysis according to the TNM stage. c Stratified survival analysis according to the serum AFP level.
Consequently, the migration-promoting effect of ITPKA is regulated by both enzyme activity-dependent and activity-independent mechanism. Besides, Ins(1,3,4,5)P₄ itself has the potential to regulate various cellular functions by acting on multiple targets, the majority of which contain pleckstrin homology (PH) domains [24]. One of earliest suggested Ins(1,3,4,5)P₄ effectors are channel proteins residing in the plasma membrane. For example, Ins(1,3,4,5)P₄ can activate K⁺ channels in the plasma membrane in cooperation with the internal Ca²⁺ [25]. In mouse lacrimal acinar cell, Ca²⁺-dependent Cl-channel is also implicated as an Ins(1,3,4,5)P₄ effector [26]. The second major class of Ins(1,3,4,5)P₄ effectors are regulators of the small G proteins Ras and Rap. Ins(1,3,4,5)P₄ plays contradicting roles in different models: Ins (1,3,4,5) P₄ promotes the activation of a unique Ras-GAP (GAP1²⁴⁷⁸), and consequently inactivation of the Ras GTPase; or inhibits RASA3 GAP activity by removing RASA3 from the plasma membrane [27–29]. Nevertheless, until now, the components of Ins(1,3,4,5)P₄-based signaling systems are far from clear. Further studies are required to define the roles of ITPKA and its products precisely in HCC.

Our study also demonstrated that high expression of ITPKA was one of the most important prognosis factors for OS and RFS in the univariate and multivariate analysis. The 5-year RFS of patients with high ITPKA expression was markedly shorter than that with low expression (26.8 % versus 57.7 %). It is known that HCC patients with the same TNM stage, histopathologic features of tumor, and treatment strategy (such as curative resection) may experience quite different clinical outcomes [30]. With the stratified survival analysis according to the TNM stage, we found that the prognostic significance of ITPKA still existed in subgroup of patients in early clinical stage (TNM stage I): the 5-year RFS for ITPKA high expression and low expression patients was 40.0 % versus 72.1 % (P = 0.001). AFP is the current gold standard and most commonly used biomarker for the diagnosis and monitoring of the effectiveness of treatment or recurrence in HCC patients [31]. Until now, there was no ideal biomarker for monitoring recurrence and metastasis in HCC patients with normal AFP level after curative resection [32, 33]. Interestingly, we found that ITPKA status could stratified the normal AFP level group into two subgroups with substantially different 5-year RFS (29.3 % and 74.2 % for ITPKA high and low patients, respectively; P = 0.047). Given that there were only 48 cases of HCC patients with normal AFP level in the present study, further investigation with a larger sample size is required to confirm this finding.

In conclusion, the results of present study for the first time demonstrated that high expression of ITPKA in HCC tumorspecimens indicated aggressive tumor behaviors and predicted a poor clinical outcome. These findings suggested that ITPKA may serve as a suitable prognostic marker for HCC patients after surgery, especially in early clinical stage.

### Abbreviations

ITPKA: Inositol-1,4,5-trisphosphate-3-kinase-A; HCC: Hepatocellular carcinoma; OS: Overall survival; RFS: Relapse-free survival; AFP: Alpha-fetoprotein; TNM: Tumor Node Metastasis; RNA-Seq: Transcriptome sequencing; ITPKs: Trisphosphate 3-kinases; Ins(1,4,5)P₃: Inositol 1,4,5-trisphosphate; Ins(1,3,4,5)P₄: Inositol 1,3,4,5-tetrakisphosphate; INPP5A: Ins(1,4,5)P₃-5-phosphatase; Ins(1,4)P₂: Inositol 1,4-bisphosphate; Ca²⁺: Calcium; F-actin: Filamentous actin; OSCC: Oral squamous cell carcinoma; qRT-PCR: Quantitative real-time reverse transcription polymerase chain reaction; PH: Pleckstrin homology; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

### Competing interests

The authors declare that they have no competing interests.

### Authors’ contributions

JL and YHZ carried out the quantitative real-time RT-PCR and western blot analysis and drafted the manuscript; PH and BZ participated in the quantitative real-time RT-PCR assay and data analysis; JS and XYG designed the study and revised the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

This work was supported by Young Talent Teachers Plan of Sun Yat-sen University (15ykpy33).

### Author details

1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Block 2, Room 708, 651 Dongfeng East Road, Guangzhou 510060, China. 2 Department of Clinical Oncology, The University of Hong Kong, L10-56, Laboratory Block, 21 Sassoon Road, Hong Kong, China. 3 Department of...
References


